KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406)

Experimental Hematology

Volumn 38, Issue 9, 2010, Pages 782-791

  Peter, Barbara ^a,b   Hadzijusufovic, Emir ^a,b   Blatt, Katharina ^a   Gleixner, Karoline V ^a   Pickl, Winfried F ^c   Thaiwong, Tuddow ^d   Yuzbasiyan Gurkan, Vilma ^d   Willmann, Michael ^b   Valent, Peter ^a,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; STEM CELL FACTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; EXON; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MAST CELL LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SYSTEMIC MASTOCYTOSIS;

EID: 77955511439     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.05.004     Document Type: Article

References (54)

1. Valent P., Akin C., Sperr W.R., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003, 122:695-717.
2. Akin C., Metcalfe D.D. Systemic mastocytosis. Annu Rev Med 2004, 55:419-432.
3. Horny H.P., Sotlar K., Valent P. Mastocytosis: state of the art. Pathobiology 2007, 74:121-132.
4. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112:946-956.
5. Valent P., Horny H.-P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of " Year 2000 Working Conference on Mastocytosis." Leuk Res 2001, 25:603-625.
6. Valent P., Akin C., Sperr W.R., et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003, 27:635-641.
7. Valent P., Ghannadan M., Akin C., et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 2004, 34:41-52.
8. Pardanani A., Akin C., Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006, 19:595-615.
9. Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am 2006, 26:575-592.
10. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995, 92:10560-10564.
11. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996, 12:312-314.
12. Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. Proc Natl Acad Sci U S A 1999, 96:1609-1614.
13. Fritsche-Polanz R., Jordan J.H., Feix A., et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001, 113:357-364.
14. Feger F., Ribadeau Dumas A., Leriche L., Valent P., Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002, 127:110-114.
15. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
16. Furitsu T., Tsujimura T., Tono T., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest 1993, 92:1736-1744.
17. London C.A., Galli S.J., Yuuki T., et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999, 27:689-697.
18. Jones C.L., Grahn R.A., Chien M.B., et al. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest 2004, 16:95-100.
19. Zemke D., Yamini B., Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002, 39:529-535.
20. Riva F., Brizzola S., Stefanello D., et al. A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest 2005, 17:385-388.
21. Gleixner K.V., Mayerhofer M., Rix U., et al. Delineation of a KIT-independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk and can be disrupted by the KIT/Lyn/Btk-targeting drug dasatinib. Blood 2007, 110:460. [abstract], Abstract 1541.
22. Frost M.J., Ferrao P.T., Hughes T.P., Ashman L.K. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002, 1:1115-1124.
23. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit. Exp Hematol 2003, 31:686-692.
24. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory type mutations. Blood 2002, 99:1741-1744.
25. Growney J.D., Clark J.J., Adelsperger J., et al. Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005, 106:721-724.
26. Gotlib J., Berube C., Growney J.D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106:2865-2870.
27. Gleixner K.V., Mayerhofer M., Aichberger K.J., et al. The tyrosine kinase-targeting drug PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of kit: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood 2006, 107:752-759.
28. Shah N.P., Lee F.Y., Luo R., Jiang Y., Donker M., Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis. Blood 2006, 108:286-291.
29. Schittenhelm M.M., Shiraga S., Schroeder A., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66:473-481.
30. Purtill D., Cooney J., Sinniah R., et al. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol 2008, 80:456-458.
31. Verstovsek S., Tefferi A., Cortes J., et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008, 14:3906-3915.
32. Gotlib J., George T.I., Linder A., et al. Phase II trial of the tyrosine kinase inhibitor PKC412 in advanced systemic mastocytosis: preliminary results. Blood 2006, 108:3609.
33. Hantschel O., Rix U., Schmidt U., et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007, 104:13283-13288.
34. Rix U., Hantschel O., Dürnberger G., et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110:4055-4063.
35. Kimura S., Naito H., Segawa H., et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106:3948-3954.
36. Yokota A., Kimura S., Masuda S., et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007, 109:306-314.
37. Pan J., Quintás-Cardama A., Manshouri T., Cortes J., Kantarjian H., Verstovsek S. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci 2007, 98:1223-1225.
38. Butterfield J.H., Weiler D., Dewald G., Gleich G.J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988, 12:345-355.
39. DeVinney R., Gold W.M. Establishment of two dog mastocytoma cell lines in continuous culture. Am J Respir Cell Mol Biol 1990, 3:413-420.
40. Rebuzzi L., Willmann M., Sonneck K., et al. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol 2007, 115:320-333.
41. Escribano L., Diaz-Agustin B., López A., et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004, 58:1-8.
42. Horny H.P., Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001, 25:543-551.
43. Krauth M.T., Födinger M., Rebuzzi L., Greul R., Chott A., Valent P. Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens. Haematologica 2007, 92:e126-e129.
44. Webster J.D., Kiupel M., Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer 2006, 6:85.
45. Van Cruchten S., Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002, 31:214-223.
46. Hadzijusufovic E., Rebuzzi L., Gleixner K.V., et al. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. Exp Hematol 2008, 36:1461-1470.
47. Gleixner K.V., Rebuzzi L., Mayerhofer M., et al. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 2007, 35:1510-1521.
48. Morey A.L., Wanigesekera G.D., Hawkins N.J., Ward R.L. C-kit mutations in gastrointestinal stromal tumours. Pathology 2002, 34:315-319.
49. Nakahara M., Isozaki K., Hirota S., et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998, 115:1090-1095.
50. Büttner C., Henz B.M., Welker P., Sepp N.T., Grabbe J. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998, 111:1227-1231.
51. Bougherara H., Subra F., Crépin R., Tauc P., Auclair C., Poul M.A. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res 2009, 7:1525-1533.
52. Ohmori K., Kawarai S., Yasuda N., et al. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells. Vet Immunol Immunopathol 2008, 126:43-53.
53. Isotani M., Ishida N., Tominaga M., et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 2008, 22:985-988.
54. Maekawa T. Innovation of clinical trials for anti-cancer drugs in Japan-proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia. Gan To Kagaku Ryoho 2007, 34:301-304.